We’re thrilled to celebrate our client, Pathos, as they expand their pipeline.

We’re thrilled to celebrate our client, Pathos, as they expand their pipeline by in-licensing a new Phase 2-ready PRMT5 inhibitor program, advancing their commitment to transformative therapies.

This brain-penetrant inhibitor opens new avenues for addressing complex diseases and supports Pathos' mission to deliver pioneering solutions for patients worldwide.

Read more about their newest addition here:

https://pathos.com/news/pathos-expands-pipeline-with-worldwide-license-of-phase-2-ready-program-a-brain-penetrant-prmt5-inhibitor/